Clinical Trial Update: An Efficacy and Safety Study of 24 Week Treatment With Mavodelpar (REN001) in Primary Mitochondrial Myopathy Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating mavodelpar (REN001) for Primary Mitochondrial Myopathy has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mitochondrial Myopathy

Drugs mentioned

• mavodelpar (REN001) (mavodelpar)

Snippet

Sponsor: Reneo Pharma Ltd | Conditions: Primary Mitochondrial Myopathy | Phase 2 | Status: COMPLETED | Results posted: 2024-04-03